Study of the usefulness of pharmacist consultations for patients on antiretroviral regimens;Enquête sur la mise en place d'une consultation pharmaceutique pour les patients sous antirétroviraux

Presse Medicale

Volumn 34, Issue 20 II, 2005, Pages 1563-1570

  Guerrault, M N ^a,b   Leclerc, C ^a   Langevin, S ^a   Merian Brosse, L ^a   Brossard, D ^a   Welker, Y ^a  

^a CHI de Poissy Saint Germain en Laye (78)   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONSULTATION; CONTROLLED STUDY; DOSIMETRY; DRUG INFORMATION; DRUG TOLERABILITY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT INFORMATION; PHARMACIST; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; TREATMENT DURATION;

EID: 29444457862     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84226-5     Document Type: Article

References (16)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
2. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of literature and clinical implications. The AIDS reader 2000, March: 177-85.
3. Bruce C, Marshall MS, Cunny KA, Lawson KA. HIV-positive males' satisfaction with pharmacy services. Journal of the American Pharmaceutical Association 1997; NS37 1: 66-75.
4. Ostrop NJ, Hallet KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother 2000; 34: 703-9.
5. Esch LD, Hardy H, Wynn H, Shelton MJ, Hewwit RG, Morse GD. Intensive adherence interventions improve virologic response to antiretroviral therapy in naïve patient. 2001, February 4-8, Chicago; abstract no 481.
6. Williams AB. Adherence to HIV regimens: 10 vital lessons. AJN 2001; 101: 37-43.
7. Davis SM. Successful ritonavir induction: intensive patient management 1997. Presented at the 4th conference on retroviruses opportunistc infections. Abstract no 541.
8. Remien RH. Adhering to HIV combination therapy: the role of the pharmacist. Pharmacy Times 1998: 28-31.
9. Janz N, Becker M. The heath belief model: a decade later. Health Educ Q 1984; 11: 1-47.
10. Moatti JP, Spire B. Duran S. Un bilan des recherches socio- comportementales sur l'observance des traitements dans le VIH : au-delà des modèles biomédicaux ? Rev Epidém et Santé Publ 2000; 48: 182-97.
11. Determinants of compliance with antiretrovial therapy in patients with HIV: prospective assessement with implications for enhancing compliance. AIDS CARE 1996.
12. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps. Abstract of the 6th Conference on retroviruses and opportunistic infection, Chicago, January 31-february 4; 1999: 84.
13. Lahlou-Laforêt K. Observance du traitement anti-rétroviral. Presse Med 2000; 22: 1227-30.
14. Greenberg RN.Overview of patient compliance with medication dosing:a literature review. Clin Ther 1984; 6: 592-9.
15. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13: 1099-107.
16. Besch CL. Compliance in clinicals trials. AIDS 1995; 9: 1-10.